Misplaced Pages

Evobrutinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 15:37, 24 December 2024 (Add: pmc, pmid, pages, issue, volume, journal, date, title, authors 1-20. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_toolbar). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 15:37, 24 December 2024 by Citation bot (talk | contribs) (Add: pmc, pmid, pages, issue, volume, journal, date, title, authors 1-20. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_toolbar)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Evobrutinib
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC25H27N5O2
Molar mass429.524 g·mol
3D model (JSmol)
SMILES
  • C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N

Evobrutinib is an experimental drug being studied for the treatment of encephalomyelitis and multiple sclerosis. It is an inhibitor of Bruton's tyrosine kinase.

References

  1. "Evobrutinib". AdisInsight.
  2. Montalban, Xavier; Piasecka-Stryczynska, Karolina; Kuhle, Jens; Benkert, Pascal; Arnold, Douglas L.; Weber, Martin S.; Seitzinger, Andrea; Guehring, Hans; Shaw, Jamie; Tomic, Davorka; Hyvert, Yann; Harlow, Danielle E.; Dyroff, Martin; Wolinsky, Jerry S. (2024). "Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study". Multiple Sclerosis Journal. 30 (4–5): 558–570. doi:10.1177/13524585241234783. PMC 11080380. PMID 38436271.
  3. Montalban, Xavier; Vermersch, Patrick; Arnold, Douglas L.; Bar-Or, Amit; Cree, Bruce A C.; Cross, Anne H.; Kubala Havrdova, Eva; Kappos, Ludwig; Stuve, Olaf; Wiendl, Heinz; Wolinsky, Jerry S.; Dahlke, Frank; Le Bolay, Claire; Shen Loo, Li; Gopalakrishnan, Sathej; Hyvert, Yann; Javor, Andrija; Guehring, Hans; Tenenbaum, Nadia; Tomic, Davorka (2024). "Safety and efficacy of evobrutinib in relapsing multiple sclerosis (EvolutionRMS1 and evolutionRMS2): Two multicentre, randomised, double-blind, active-controlled, phase 3 trials". The Lancet Neurology. 23 (11): 1119–1132. doi:10.1016/S1474-4422(24)00328-4. PMID 39307151.
  4. "Evobrutinib". Multiple Sclerosis Trust.
Categories:
Evobrutinib Add topic